Randomization and baseline transmission in vaccine field trials
- PMID: 17291359
- PMCID: PMC2870563
- DOI: 10.1017/S0950268806006716
Randomization and baseline transmission in vaccine field trials
Erratum in
- Epidemiol Infect. 2007 Aug;135(6):1055
Abstract
In randomized trials, the treatment assignment mechanism is independent of the outcome of interest and other covariates thought to be relevant in determining this outcome. It also allows, on average, for a balanced distribution of these covariates in the vaccine and placebo groups. Randomization, however, does not guarantee that the estimated effect is an unbiased estimate of the biological effect of interest. We show how exposure to infection can be a confounder even in randomized vaccine field trials. Based on a simple model of the biological efficacy of interest, we extend the arguments on comparability and collapsibility to examine the limits of randomization to control for unmeasured covariates. Estimates from randomized, placebo-controlled Phase III vaccine field trials that differ in baseline transmission are not comparable unless explicit control for baseline transmission is taken into account.
References
-
- Smith PG, Morrow RH. Methods for Field Trials of Interventions Against Tropical Diseases: A Toolbox. Oxford: Oxford University Press; 1991.
-
- Efron B. Forcing a sequential experiment to be balanced. Biometrika. 1971;58:403–417.
-
- Greenland S, Robins JM. Identifiability, exchangeability, and epidemiologic confounding. International Journal of Epidemiology. 1986;15:412–418. - PubMed
-
- Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. American Journal of Epidemiology. 1987;125:761–768. - PubMed
-
- Gail MH, Moolgavkar SH, Prentice RL. Modern Statistical Methods. New York: Wiley; 1986. Adjusting for covariates that have the same distribution in exposed and unexposed cohorts; pp. 3–18. , pp.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
